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Cellular senescence 15 
Cellular senescence was originally described as the limited proliferative capacity of cultured human 16 
fibroblasts1. This phenomenon, now termed replicative senescence, is caused by telomere erosion. 17 
Currently, it is generally accepted that senescence can be prematurely induced by many different insults, 18 
including oxidative stress, genotoxic stress, epigenetic changes, metabolic dysfunction, over activation of 19 
oncogenes or loss of some tumor suppressor genes, and mitochondrial dysfunction2. 20 
The main defining characteristic of senescence is permanent growth arrest, and p53-p21 and p16INK4a –21 
pRB are the two essential pathways responsible for this replicative arrest3. Interestingly, both p53 and 22 
p16INK4a are the most commonly mutated genes in cancer, suggesting that one of the evolutionary 23 
advantages of the senescence response is to suppress the development of cancer4. 24 
In addition to the growth arrest, which is a necessary but insufficient marker of senescent cells, many 25 
features and molecular markers are used for identifying senescence. For instance, a commonly used 26 
marker is the senescence-associated beta-galactosidase staining (SA-βgal)5. The increase in SA-βgal 27 
activity is thought to be a consequence of increased lysosomal mass6,7. Due the fact that there is no 28 
universal marker, the combination of many senescence-associated hallmarks is currently used for the 29 
unequivocal characterization and identification of senescent cells8.  30 
Although p16INK4a is expressed by many but not all senescent cells, it is now generally accepted to be one 31 
of the most specific senescence markers in vivo9,10. This led to the design of two distinct mouse models 32 
where p16INK4a-positive cells can be selectively eliminated11,12. These models contributed much to our 33 
understanding about the causal roles of senescent cells in many different processes that include aging, 34 
age-related diseases, and wound healing11-18.  35 
Numerous senescence inducers can cause genomic damage that can remain unresolved. As a result, the 36 
DNA damage response (DDR) is constantly active because of the chronic persistence of DNA damage 37 
foci. Those foci are generally termed DNA-SCARS (DNA segments with chromatin alterations 38 
reinforcing senescence)19. The persistent DDR signaling function as one of the main drivers of the 39 
expression of the senescence associated secretory phenotype (SASP)20. 40 
The SASP is a complex mixture of secreted factors that can be divided in 3 main categories: 1) factors 41 
binding to receptors (soluble signaling molecules, such as cytokines, chemokines, and growth factors), 2) 42 
factors acting directly (matrix metalloproteases,  serine proteases and small non-protein components, such 43 
as reactive oxygen (ROS) and nitrogen species), and 3) regulatory factors (tissue inhibitors of 44 
metalloproteases, the plasminogen activator inhibitor, and insulin-like growth factor binding proteins) 21. 45 
In addition to secreted factors, senescent cells can also influence their surrounding through juxtacrine 46 
NOTCH/JAG1 signaling22 or via intercellular transfer of different molecules through cytoplasmic 47 
bridges23 or exosomes release24. Importantly, some SASP components can reinforce senescence25 and 48 
induce senescence in neighboring cells (paracrine senescence)26. 49 
It is clear now that the composition of SASP factors is dependent on the type of cells and senescence 50 
inducers27. Moreover, the SASP can be regulated at different levels and it seems that most of the 51 
pathways that are important for the establishment of this phenotype converge into activation of the NF-κB 52 
and the C/EBPβ  pathway21. Strikingly, the mechanistic target of rapamycin (mTOR) pathway, an 53 
essential player in the aging process, is an important node in SASP regulation28-30.  54 
Many age-related diseases, if not all, share a chronic low-grade inflammatory state referred to as 55 
inflammaging31. Elimination of senescent cells reduces many proinflammatory factors such as IL-6, IL-1α 56 
and TNF- α17, suggesting that the SASP is, at least in part, causing this increased inflammatory state in 57 
old tissues. Given the fact that senescent cells are present in a small percentage in old tissues32, it is highly 58 
plausible that the positive effect seen after senescent cells elimination is a consequence of SASP 59 
suppression.  60 
Growing body of evidence has demonstrated the implication of senescence in aging and age-related 61 
pathologies. Hence, targeting senescent cells either by eliminating them using “senolytics” or inhibiting 62 
the deleterious effect of SASP, might be a promising approach for enhancing healthy longevity33. Several 63 
literature reviews have covered the pharmacological elimination of senescent cells elsewhere33-35.  64 
However, another plausible approach is to avoid the formation of senescent cells by preventing cellular 65 
damage, and accumulating data in experimental animal models and humans suggest that caloric restriction 66 
(CR) without malnutrition may be a promising intervention in this context. 67 
 68 
Calorie restriction 69 
Calorie restriction (CR) with adequate nutrient intake is the most powerful non-genetic intervention for 70 
extending healthspan and lifespan in multiple animal models, including yeast, fruit flies, worms, and 71 
rodents36. In most strains of rats and mice a reduction of dietary calories by 20 up to 50% results in a 72 
substantial extension of both average and maximal lifespan, even if mice with different genotypes 73 
respond differently to the same degree of restriction37. Not only these CR animals, supplied with the 74 
appropriate amount of calories and nutrients, live significant longer, but many of the typical age-75 
associated chronic diseases are either prevented or delayed. For example, the incidence of cancer, the 76 
leading cause of death in rodents, is drastically reduced in CR animals; similar reductions or slowing 77 
down of disease progression have been observed for nephropathy, cardiomyopathy, diabetes, chronic lung 78 
diseases, autoimmune diseases and neurodegenerative disease36,37.  79 
Accumulating data indicate that CR extends lifespan also in non-human primates38. In Rhesus monkeys, 80 
CR significantly improves metabolic health, prevents obesity, glucose intolerance/type 2 diabetes, and 81 
postpones the onset of sarcopenia, hearing loss and atrophy of certain key subcortical regions of the brain, 82 
including the caudate and putamen and the left insula (34). Moreover, CR in monkeys reduces morbidity 83 
and mortality for cancer, cardiovascular disease and frailty39,40. Indeed, in contrast to the scientifically 84 
unsupported opinion that long-term CR promotes frailty41-43, recent data from the Wisconsin CR Primate 85 
study clearly show that the levels of weakness, poor endurance, slowness, low physical activity and frailty 86 
were significantly lower in the CR than in the ad-libitum fed monkeys44. 87 
In humans, calorie restriction with adequate intake of vitamins and minerals causes many of the same 88 
physiological, metabolic and molecular adaptations observed in CR animals. For example, moderate CR 89 
leads to major improvements in all the classical cardiovascular risk factors, over and above those 90 
conferred by weight loss, even when implemented in healthy young and middle-aged non-obese men and 91 
women. Interestingly, these cardiometabolic adaptations are coupled with improvements in cardiac and 92 
arterial function, including improvements in left ventricular diastolic function and heart rate variability45. 93 
Like in small mammals, CR in humans causes major modifications of several hormones that are 94 
implicated in the pathogenesis of cancer and in the biology of aging46. Serum concentrations of insulin, 95 
testosterone, estradiol and several inflammatory markers were significantly lower, while IGFBP-1, 96 
SHBG, adiponectin and cortisol concentration were higher in people practicing CR group than in controls 97 
eating Western diets ad-libitum45. Plasma triiodothyronine concentration, and as a consequence 98 
average 24‐ hour, day‐ time and night‐ time core body temperature, were also significantly reduced, 99 
supporting a strong CR-mediated inhibitory effect on metabolic rate and oxidative stress47.  100 
 101 
CR-mediated molecular mechanisms promoting health and longevity 102 
The mechanisms mediating the health benefits of CR are not fully understood. Multiple systemic 103 
metabolic, neuroendrocrine and immunological adaptations coupled with cell-specific molecular 104 
mechanisms are involved. For example, calorie restriction without malnutrition exerts a powerful effect in 105 
improving insulin sensitivity and in reducing protein glycation, oxidative stress and free radical-induced 106 
cellular damage48-50.  The CR induced reduction of multiple anabolic hormones and growth factors causes 107 
a down-regulation of the nutrient-sensing insulin/IGF signaling network and an activation of FOXO, 108 
which modifies several “longevity genes”51, including endogenous antioxidant enzymes (e.g. SOD2, 109 
catalase), DNA repair (e.g. DDB1) and autophagy (e.g. beclin-1, autophagin-1) genes52. Autophagy and 110 
mitophagy are important for the removal of dysfunctional organelles, amyloid and other protein 111 
aggregates that interfere with normal cell function53. FOXO activation is also a powerful inhibitor of 112 
cyclin D, a master regulator of cell cycle progression and cell proliferation. Another major adaptation to 113 
CR is the reduction in plasma concentrations of inflammatory cytokines and a modest increase in 114 
circulating cortisol that results in a reduction in systemic inflammation together with a protection against 115 
aging-associated deterioration in immune function54,55. Increased expression of protein chaperones such as 116 
heat shock protein-70 is also important to improve proteostasis, the removal of damaged cellular proteins 117 
and cellular stress resistance50,56. As we will discuss later, other molecular effectors that have been shown 118 
to mediate the health effects of CR include TOR57, AMPK58, sirtuins59, and NRF260. Energy and amino 119 
acids restriction cause an inhibition of mTORC1 activity, which in turn enhances autophagy, improves 120 
proteostasis and stem cell function61. Overexpression of sirtuins (i.e. SIRT1, SIRT3 and SIRT6) improves 121 
metabolic homeostasis through histone deacetylation, inhibits NF-kB signaling and increases genomic 122 
stability59. In addition, activation of AMPK and SIRT1 up-regulates PGC-1a, a key transcriptional factor 123 
regulating mitochondrial function, antioxidant defenses, and fatty acid oxidation62.  124 
CR and cellular senescence 125 
Different studies have shown that CR reduce senescence markers in different mouse organs and human 126 
colon mucosa9,63-66. One of the main inducers of senescence is cellular damage. Therefore, it is highly 127 
plausible that CR reduces the generation of senescent cells by preventing damage to occur. CR can 128 
protect cellular deterioration in at least two major ways: interfering with the source of damage, for 129 
example via decreasing oxidative stress and inflammation, or repairing/eliminating already present 130 
damage, for example by increasing autophagy (Figure 1)49,50,54.  131 
An important source of cellular damage is oxidative stress, mainly caused by an accumulation of reactive 132 
oxygen species (ROS). Historically, the beneficial effects of CR were thought to be the result of slow 133 
metabolism resulting in reduced production of ROS 67, but it is now known that CR can actively regulate 134 
many other defense mechanisms against oxidative stress52,68. Numerous experiments have established that 135 
sirtuins are critically required to reduce oxidative stress. In accordance, CR induces the expression of 136 
SIRT3, which was shown to play an essential role in reducing oxidative damage and its related 137 
pathologies 69,70. It is interesting to note that mitochondrial dysfunction caused by SIRT3 downregulation 138 
can, in fact, induces senescence 71. Another member of the sirtuin family, SIRT1, was reported to mediate 139 
aspects of CR response 72. Due to the fact that some studies have demonstrated the important role of 140 
SIRT1 in regulating oxidative status within the cell 73, it is highly possible that SIRT1 mediates its effect 141 
during CR by reducing levels of oxidative stress. These notions suggest that CR might prevent 142 
senescence, in part, by upregulating the antioxidant defense program partly through the increase of 143 
sirtuins function and in part through up-regulation of FOXO. 144 
Autophagy, a major lysosomal degradation pathway that is activated by CR, might act as an anti-145 
senescence mechanism by clearance of damaged proteins and organelles including damaged 146 
mitochondria50,74. Intriguingly, selective elimination of dysfunctional mitochondria by mitophagy 147 
alleviate many aspects of the senescence phenotype75. 148 
Another mechanism by which CR can prevent senescence is through enhancement of DNA repair 149 
mechanisms. Interestingly, CR activates many pathways that can prevent and aid in resolving DNA 150 
lesions. For instance, CR reduces age-dependent decline in non-homologous end joining (NHEJ)76. In 151 
addition, it can improve nucleotide excision repair (NER), increase the fidelity of polymerase alpha and 152 
beta, and decrease their age dependent decline77,78 . Moreover, CR can also protect DNA by inducing the 153 
base excision repair pathway (BER), both in young and aged animals79.  154 
It has been shown that CR can regulate longevity pathways that include the insulin/insulin growth factor I 155 
signaling (IIS), both in rodents and human. Circulating IGF-1 levels were decreased during CR in rodents 156 
80, whereas in human the effect was not direct. Long‐ term CR results in a persistent increase in serum 157 
IGFBP‐ 1 leading to a decrease in IGF‐ 1:IGFBP‐ 1 ratio levels, which can probably inhibit IGF-1 158 
signaling by decreasing free IGF‐ 1 in circulation81. Notably, prolonged exposure of cells to IGF-1 can 159 
induce premature senescence through the regulation of SIRT1-p53 pathway82. Accordingly, the decrease 160 
in IGF-1 activity, as a consequence of CR, might help in preventing premature senescence. 161 
Finally, the mechanistic target of rapamycin (mTOR) is also negatively affected by CR. A large portion of 162 
the senescence associated secretory phenotype components is regulated by mTOR28, including factors that 163 
can induce secondary senescence83. In addition, mTOR can promote geroconversion, the conversion from 164 
a proliferative arrest to irreversible senescence, and mitigation of its activity favors quiescence84. For 165 
these reasons, CR could also prevent the activation and spread of senescence by inhibiting mTOR. 166 
Conclusion  167 
CR is a well-established intervention for reducing age-associated chronic diseases and enhancing lifespan. 168 
In this review, we have summarized some of the mechanisms by which CR exerts its beneficial effects, 169 
highlighting their complexity and heterogeneity. However, reduction of cellular damage might well be 170 
related, at least in part, to prevention of cellular senescence. In the next few years, it will be key to 171 
monitor the effects of long-term CR on cell senescence in various tissues to determine whether there is 172 
any organ-specificity for damage protection. It will be also of high interest to treat animals under CR with 173 
senolytic drugs to prove any synergistic effect of lowering cellular damage and eliminating senescent 174 
cells. Another important question is whether the absence of senescent cells during CR might trigger side 175 
effects – for example promoting longer kinetic of wound healing, a known issue for animals under CR85. 176 
Finally, similar studies on the prevention of senescent cells should be directed towards alternative and less 177 
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